MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014

Wilmington, DE, September 25, 2009 --(PR.com)-- According to a new market research report, ‘Global biosimilars Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the global biosimilars market is expected to be worth US$19.4 billion by 2014, recording a CAGR of 89.1% from 2009 to 2014. The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market.

Browse more than 60 market data tables and in-depth TOC on biosimilars market.

Early buyers will receive 10% customization of reports.

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

Currently, the biosimilars market is highly fragmented and its huge opportunities are attracting new players. Favourable regulatory developments in the biosimilars sector are expected to increase the market share and profit margins while reducing medical expenditure.

Asia’s early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars product market. The American market (including North America and Latin America) is expected to account for nearly 35.3% of the total revenues in 2014. The European market is also gaining momentum after the approval of its first biosimilars Omnitrope in 2006.

Recombinant non-glycosylated proteins form the largest segment in biosimilars market, with an estimated $11.5 billion by 2014. This market has a high CAGR of 87.9% from 2009 to 2014 mainly because most of the branded blockbuster biopharmaceutical drugs such as interferon, human growth hormone (Somatropin), insulin and G-CSF, belong to this class and have wide range of applications.

Scope of the Report
This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

Biosimilars product market: Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others
Biosimilars service market: Contract research and manufacturing services, clinical trials services
Biosimilars applications market: Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases
Biosimilars technology market: Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

MarketsandMarkets is a research and consulting firm that publishes 120 market research reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at www.marketsandmarkets.com.

Ms. Sunita
108, West 13th Street,
Wilmington, DE, 19801
County of New Castle
Tel: +1-888-989-8004
Email: sales@marketsandmarkets.com

###